Anubha Mahajan - Genetic Mutations

Author Information

Dr. Anubha Mahajan is affiliated with The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK. Dr. Mahajan has made significant contributions to the field of genetics, particularly in the areas of genetic variants associated with human height, metabolic diseases, type 2 diabetes, and genetic associations with exercise-related adaptations.

Research Contributions

Dr. Anubha Mahajan has a notable research portfolio, with a focus on understanding the genetic underpinnings of various human traits and diseases. Some of her significant works include the identification of common genetic variants associated with human height from a diverse cohort of 5.4 million individuals, and the exploration of genetic effects underlying type 2 diabetes in South Asian and European populations. Additionally, she has conducted studies evaluating human genetic support for hypothesized metabolic disease genes and investigating the genetic variation at RAB3GAP2 in relation to exercise-related adaptation and recovery. Her research further delves into the etiological and clinical heterogeneity in newly diagnosed type 2 diabetes individuals and the causal relationship between central adiposity, diabetes, and kidney stone disease.

Aliases

Dr. Anubha Mahajan is also known by the aliases A Mahajan and A. Mahajan.

Publication and Citation Metrics

Metrics	Value
Citation Count	32,043
H-index	75
Paper Count	322

Publications:

A Saturated Map of Common Genetic Variants Associated with Human Height from 5.4 Million Individuals of Diverse Ancestries

DOI: 10.1101/2022.01.07.475305

Year: 2022

Evaluating human genetic support for hypothesized metabolic disease genes.

DOI: 10.1016/j.cmet.2022.03.011

Year: 2022

Identification of genetic effects underlying type 2 diabetes in South Asian and European populations

DOI: 10.1038/s42003-022-03248-5

Year: 2022

Conservative management of asymptomatic pelvi – ureteric junction obstruction ( A-PUJO ) – is it safe ? – a cohort study

DOI:

Year: 2022

Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study

DOI: 10.1016/j.xcrm.2021.100477

Year: 2022

Genetic variation at RAB3GAP2 and its role in exercise-related adaptation and recovery

DOI: 10.21203/rs.3.rs-701652/v1

Year: 2021

Analysis of overlapping genetic association in type 1 and type 2 diabetes

DOI: 10.1101/2020.06.17.156778

Year: 2021

Central adiposity and diabetes are causally associated with kidney stone disease

DOI: 10.1530/endoabs.77.p54

Year: 2021

Publisher Correction: Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability.

DOI: 10.1038/s41467-021-21276-3

Year: 2021

Variation in the SERPINA6/SERPINA1 locus alters morning plasma cortisol, hepatic corticosteroid binding globulin expression, gene expression in peripheral tissues, and risk of cardiovascular disease

DOI: 10.1038/s10038-020-00895-6

Year: 2021

What Causes CNVs?

What are TALENs?

What Types of Genetic Mutations Can Benzene Cause?

What Are the Ethical Considerations for CRISPR Technology?

How Do Genetic Mutations Affect Fertility?

How Does Polyploidy Occur?

What Types of Cancers Are Linked to Asbestos Exposure?

Are All Nucleotide Mutations Harmful?

How Are Nucleotide Mutations Detected?

Can Mutations Be Prevented or Controlled?

Partnered Content Networks

Relevant Topics